Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13683429 | 0.98 | CYP1A2 (0.33) | CYP1A2CYP2D6CYP2C19CYP2C9TSHR | |
| SCHEMBL9281036 | 0.96 | SLC6A2 (0.33) | CYP1A2CYP2D6CYP2C19CYP2C9TSHR | |
| SCHEMBL9284842 | 0.90 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8768114 | 0.85 | CYP2D6 (0.39) | CYP1A2CYP2D6CYP2C19CYP2C9TSHR | |
| SCHEMBL12449085 | 0.80 | LTA4H (0.38) | CYP1A2CYP2D6CYP2C19CYP2C9TSHR | |
| SCHEMBL24926212 | 0.80 | — | — | |
| SCHEMBL9281135 | 0.79 | ADH1A (0.41) | CYP1A2CYP2D6CYP2C19CYP2C9TSHR | |
| SCHEMBL24080142 | 0.78 | LTA4H (0.36) | CYP2D6CYP2C9TSHRHSD17B10LTA4H | |
| SCHEMBL9284267 | 0.77 | ADH1A (0.38) | CYP1A2CYP2D6CYP2C19CYP2C9TSHR | |
| SCHEMBL13082953 | 0.77 | ADH1A (0.42) | CYP1A2TSHRLTA4HSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TETRAPHASE PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2019-03-14 | — | — | US | disclosed |
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-9315451-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20120135968-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | CYP1A2 844/4885CYP2D6 565/4885CYP2C19 287/4885 |
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | MCL1, ABL1, MALT1 | CYP1A2 3991/4885CYP2D6 3911/4885CYP2C19 3708/4885 |
| US-20120135968-A1 | Tetracycline Compounds | TUBB, TUBA1C, TUBA1A | CYP1A2 844/4885CYP2D6 565/4885CYP2C19 287/4885 |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | CYP1A2 844/4885CYP2D6 565/4885CYP2C19 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.